Huluwa Pharmaceutical Group Officially Establishes the Academician Zhang Qiang Workstation to Accelerate Innovation in Pediatric Drug R&D

On May 8, 2025, the Hainan Provincial Department of Science and Technology issued a public announcement stating that, in accordance with the Hainan Provincial Measures for the Administration of Academician Workstations, Hainan Huluwa Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Huluwa Pharmaceutical") has been officially approved to establish the Academician Zhang Qiang Workstation. This initiative marks a key milestone for Huluwa Pharmaceutical in the field of innovative drug R&D. It will further integrate the nanomedicine drug delivery technology expertise of Academician Zhang Qiang's team from the Chinese Academy of Engineering with the company's extensive experience in pediatric pharmaceuticals, thereby promoting the deep integration of cutting-edge formulation technologies and industrial applications.

Academician Zhang Qiang is a leading authority in pharmaceutical sciences in China. He has long been engaged in research on innovative drug delivery systems and has achieved breakthrough results, particularly in the fields of nanomedicine targeted delivery and non-injectable administration of macromolecular drugs. The self-microemulsifying technology for cyclosporine soft capsules developed by his team broke foreign monopolies and increased the solubility of poorly soluble drugs by a thousand-fold. In the field of active targeted delivery of antitumor nanomedicines, his work is internationally leading. Through this collaboration, both parties will focus on applying new technologies to improve medication safety and patient adherence, while exploring pathways for integrating the modernization of traditional Chinese medicine with nanodelivery technologies.

As one of the leading enterprises in China's pediatric traditional Chinese medicine sector, Huluwa Pharmaceutical Group places strong emphasis on R&D innovation and has ranked 40th on the "Top 100 Chinese Traditional Chinese Medicine Enterprises" list. At the beginning of 2025, the company successively obtained approvals for major new products such as Salbutamol Sulfate Solution for Inhalation and Calcitriol Soft Capsules. The total number of generic drugs that have passed consistency evaluation has increased to 28, and the development of eight Class I innovative traditional Chinese medicines is progressing smoothly, covering high-incidence pediatric diseases in areas such as the respiratory and digestive systems.

The policy advantages of the Hainan Free Trade Port provide a unique enabling environment for pharmaceutical innovation. The high priority given to fertility support and children's health under China's 14th Five-Year Plan has further driven demand in the pediatric pharmaceutical market. Huluwa Pharmaceutical will leverage the Academician Zhang Qiang Workstation to advance the integration of the "laboratory-clinical-industrialization" translational chain, supporting the upgrading of Hainan's biopharmaceutical industry toward high-end and intelligent development.